Tri-Specific TACA Fusion Proteins With Half-Life Extension
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing immunotherapies targeting tumor-associated carbohydrate antigens (TACAs) have short half-lives, requiring frequent administration to achieve therapeutic effects, and there is a need for improved pharmacokinetic properties to target multiple common cancers effectively.
Innovation Solution
Development of tri-specific fusion proteins with a half-life extension domain, comprising molecules like PEG or Fc domains, to enhance the serum half-life of immunotherapeutics that target TACAs, thereby improving their persistence in the body.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional immunotherapies (bi-specific antibodies, CAR T cells) are used to target TACAs, then T cell mediated killing of cancer cells is achieved, but the therapeutic molecules are rapidly eliminated from the body requiring large or multiple doses
Solution Approach 1:
The patent creates a tri-specific fusion protein that combines three distinct functional domains: a TACA-binding domain (from lectin), a CD3-binding domain (scFv), and a half-life extension domain (Fc region or PEG). This composite structure integrates the antigen-targeting capability with pharmacokinetic enhancement, allowing the therapeutic to maintain effective concentrations in the body for extended periods while retaining its cancer-killing function
Solution Approach 2:
The Fc region or PEG acts as an intermediary element that mediates between the antigen-binding function and the body's clearance mechanisms. By incorporating this half-life extension domain, the protein gains extended circulation time without compromising its primary function of recruiting T cells to kill TACA-expressing cancer cells
2Reliability
If large doses or multiple doses of GlyTR are administered to achieve therapeutic effect, then desired therapeutic effect is achieved, but the treatment complexity and burden increase
Solution Approach 1:
The patent changes the pharmacokinetic parameters of the immunotherapeutic by adding a half-life extension domain. This modification alters the elimination rate constant and mean residence time of the protein in the body, allowing sustained therapeutic effects at lower doses and reducing the frequency of administrations from multiple doses to potentially single or less frequent doses
3Adaptability or versatility
If bi-specific proteins are designed to target multiple cancer types through TACA binding, then broad cancer targeting capability is achieved, but the proteins are rapidly cleared requiring frequent re-administration
Solution Approach 1:
The tri-specific fusion protein achieves multi-functionality by combining universal TACA recognition (applicable across multiple cancer types) with extended half-life properties. The lectin-derived TACA-binding domain provides broad cancer targeting capability, while the Fc region or PEG confers universal half-life extension, making the protein both versatile in application and persistent in the body
Data Source
AI summary
Provided are compositions and methods for treating diseases associated with aberrant glycosylation of cell surface molecules and expression of tumor-associated carbohydrate antigens (TACA). Also provided are fusion proteins specific to tumor-associated carbohydrate antigens (TACA) comprising a half-life extender molecule, vectors encoding the TACA-fusion proteins, and recombinant cells comprising the TACA-specific fusion proteins.